Found 48 Enz. Inhib. hit(s) with all data for entry = 7348 TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: >2.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Hydra Biosciences
US Patent
Hydra Biosciences
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
